Dongwha Pharm.Co.,Ltd (000020.KS)
KRW 6360.0
(-1.7%)
KRW 6360.0
(-1.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -24.06 Billion KRW | 13.08% |
| 2022 | -27.68 Billion KRW | 43.51% |
| 2021 | -49 Billion KRW | -14.21% |
| 2020 | -42.9 Billion KRW | -38.99% |
| 2019 | -30.86 Billion KRW | 23.99% |
| 2018 | -40.61 Billion KRW | -28.58% |
| 2017 | -31.58 Billion KRW | 11.59% |
| 2016 | -35.73 Billion KRW | 16.69% |
| 2015 | -42.88 Billion KRW | -49.84% |
| 2014 | -28.62 Billion KRW | -29.14% |
| 2013 | -22.16 Billion KRW | -172.98% |
| 2012 | -8.11 Billion KRW | -22.38% |
| 2011 | -6.63 Billion KRW | -126.96% |
| 2010 | 24.6 Billion KRW | 11.3% |
| 2009 | 22.1 Billion KRW | -5.39% |
| 2008 | 23.36 Billion KRW | 1474.38% |
| 2007 | 1.48 Billion KRW | 350.44% |
| 2006 | 329.53 Million KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.94 Billion KRW | 88.44% |
| 2024 Q1 | -26.78 Billion KRW | -11.31% |
| 2023 Q3 | -90.23 Billion KRW | -19.51% |
| 2023 Q4 | -24.06 Billion KRW | 73.33% |
| 2023 Q1 | -48.25 Billion KRW | -74.3% |
| 2023 Q2 | -75.5 Billion KRW | -56.48% |
| 2023 FY | -24.06 Billion KRW | 13.08% |
| 2022 Q3 | -40.59 Billion KRW | -11.14% |
| 2022 Q4 | -27.68 Billion KRW | 31.81% |
| 2022 FY | -27.68 Billion KRW | 43.51% |
| 2022 Q2 | -36.52 Billion KRW | 42.56% |
| 2022 Q1 | -63.59 Billion KRW | -29.77% |
| 2021 Q4 | -49 Billion KRW | -73.62% |
| 2021 Q2 | -25.99 Billion KRW | 41.51% |
| 2021 FY | -49 Billion KRW | -14.21% |
| 2021 Q3 | -28.22 Billion KRW | -8.58% |
| 2021 Q1 | -44.44 Billion KRW | -3.59% |
| 2020 Q3 | -56.37 Billion KRW | 46.36% |
| 2020 FY | -42.9 Billion KRW | -38.99% |
| 2020 Q1 | -69.27 Billion KRW | -124.41% |
| 2020 Q2 | -105.09 Billion KRW | -51.71% |
| 2020 Q4 | -42.9 Billion KRW | 23.88% |
| 2019 Q4 | -30.86 Billion KRW | 15.34% |
| 2019 FY | -30.86 Billion KRW | 23.99% |
| 2019 Q3 | -36.46 Billion KRW | -41.42% |
| 2019 Q2 | -25.78 Billion KRW | 22.93% |
| 2019 Q1 | -33.45 Billion KRW | 17.63% |
| 2018 Q3 | -33.75 Billion KRW | 5.94% |
| 2018 Q2 | -35.88 Billion KRW | -0.91% |
| 2018 Q1 | -35.56 Billion KRW | -12.59% |
| 2018 FY | -40.61 Billion KRW | -28.58% |
| 2018 Q4 | -40.61 Billion KRW | -20.32% |
| 2017 Q4 | -31.58 Billion KRW | 18.67% |
| 2017 Q3 | -38.83 Billion KRW | 5.95% |
| 2017 Q1 | -39.92 Billion KRW | -11.73% |
| 2017 FY | -31.58 Billion KRW | 11.59% |
| 2017 Q2 | -41.29 Billion KRW | -3.44% |
| 2016 FY | -35.73 Billion KRW | 16.69% |
| 2016 Q2 | -52.98 Billion KRW | -11.55% |
| 2016 Q3 | -48.21 Billion KRW | 9.0% |
| 2016 Q4 | -35.73 Billion KRW | 25.89% |
| 2016 Q1 | -47.49 Billion KRW | -10.74% |
| 2015 Q4 | -42.88 Billion KRW | -17.94% |
| 2015 Q3 | -36.36 Billion KRW | -7.46% |
| 2015 Q2 | -33.84 Billion KRW | 7.33% |
| 2015 Q1 | -36.51 Billion KRW | -27.59% |
| 2015 FY | -42.88 Billion KRW | -49.84% |
| 2014 Q1 | -25.29 Billion KRW | -14.12% |
| 2014 FY | -28.62 Billion KRW | -29.14% |
| 2014 Q4 | -28.62 Billion KRW | 0.11% |
| 2014 Q3 | -28.65 Billion KRW | -9.5% |
| 2014 Q2 | -26.16 Billion KRW | -3.46% |
| 2013 Q4 | -22.16 Billion KRW | -2.56% |
| 2013 FY | -22.16 Billion KRW | -172.98% |
| 2013 Q1 | -20.6 Billion KRW | -153.8% |
| 2013 Q2 | -23.72 Billion KRW | -15.12% |
| 2013 Q3 | -21.61 Billion KRW | 8.9% |
| 2012 Q2 | -23.93 Billion KRW | 9.94% |
| 2012 Q1 | -26.58 Billion KRW | -300.67% |
| 2012 Q4 | -8.11 Billion KRW | 69.96% |
| 2012 FY | -8.11 Billion KRW | -22.38% |
| 2012 Q3 | -27.02 Billion KRW | -12.91% |
| 2011 Q4 | -6.63 Billion KRW | -267.15% |
| 2011 Q1 | 23.81 Billion KRW | -3.24% |
| 2011 FY | -6.63 Billion KRW | -126.96% |
| 2011 Q3 | 3.96 Billion KRW | -66.02% |
| 2011 Q2 | 11.68 Billion KRW | -50.95% |
| 2010 Q3 | 32.56 Billion KRW | 5.12% |
| 2010 FY | 24.6 Billion KRW | 11.3% |
| 2010 Q4 | 24.6 Billion KRW | -24.43% |
| 2010 Q1 | 19.97 Billion KRW | 0.0% |
| 2010 Q2 | 30.97 Billion KRW | 55.08% |
| 2009 Q2 | 19.58 Billion KRW | -16.18% |
| 2009 Q1 | 23.36 Billion KRW | 24.48% |
| 2009 FY | 22.1 Billion KRW | -5.39% |
| 2009 Q3 | 18.89 Billion KRW | -3.54% |
| 2008 Q4 | 18.77 Billion KRW | 1228.4% |
| 2008 Q1 | 1.48 Billion KRW | 598.42% |
| 2008 Q2 | 873.54 Million KRW | -41.15% |
| 2008 FY | 23.36 Billion KRW | 1474.38% |
| 2008 Q3 | 1.41 Billion KRW | 61.78% |
| 2007 FY | 1.48 Billion KRW | 350.44% |
| 2007 Q2 | -894.62 Million KRW | 0.0% |
| 2007 Q3 | 717.23 Million KRW | 180.17% |
| 2007 Q4 | 212.52 Million KRW | -70.37% |
| 2006 FY | 329.53 Million KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 373.359% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 104.206% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 107.74% |
| HANDOK Inc. | 283.45 Billion KRW | 108.489% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 219.876% |
| Yuhan Corporation | -69.18 Billion KRW | 65.222% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 112.406% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | -552.819% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 104.646% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 25.809% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 131.796% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 165.319% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 129.159% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 195.831% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 373.359% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 84.947% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 111.974% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 114.076% |
| JW Holdings Corporation | 480.68 Billion KRW | 105.006% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 114.62% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | 20572.57% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 115.587% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 1123.328% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 204.61% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 113.752% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 146.295% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 373.359% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 115.2% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 106.718% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 115.587% |
| Yuhan Corporation | -69.18 Billion KRW | 65.222% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 117.694% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 140.322% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 105.607% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 115.587% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 120.701% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 246.493% |
| CKD Bio Corp. | 143.29 Billion KRW | 116.792% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 120.731% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 46.212% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 1123.328% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 105.69% |
| Boryung Corporation | 187.72 Billion KRW | 112.817% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 66.507% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 131.796% |
| JW Lifescience Corporation | 26.09 Billion KRW | 192.223% |